Allergan's Top-Line Phase 3 Results for Abicipar Don't Shift Our View for Now
We're leaving our fair value estimate unchanged for wide-moat Allergan following the announcement of top-line results from two phase 3 clinical trials (Sequoia and Cedar) for abicipar pegol, the company's DARPin anti-VEGF for age-related macular degeneration. Although the initial data set is limited, there's some reason for optimism as the drug's eight-week and 12-week dosing regimen met the primary clinical endpoint of noninferiority to more frequent monthly injections of Lucentis for proportio...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.